Search

Author/Creator DiSimone, Christopher

1. Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. Issue 9 (20th March 2021)

Authors:
McDermott, David F.; Lee, Jae-Lyun; Bjarnason, Georg A.; Larkin, James M. G.; Gafanov, Rustem A.; Kochenderfer, Mark D.; Jensen, Niels Viggo; Donskov, Frede; Malik, Jahangeer; Poprach, Alexandr; Tykodi, Scott S.; Alonso-Gordoa, Teresa; Cho, Daniel C.; Geertsen, Poul F.; Climent Duran, Miguel Ange...
Journal:
Journal of clinical oncology
Issue:
Volume 39:Issue 9(2021)
Page Start:
1020
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Issue 7 (July 2021)

Authors:
Powles, Thomas; Csőszi, Tibor; Özgüroğlu, Mustafa; Matsubara, Nobuaki; Géczi, Lajos; Cheng, Susanna Y-S; Fradet, Yves; Oudard, Stephane; Vulsteke, Christof; Morales Barrera, Rafael; Fléchon, Aude; Gunduz, Seyda; Loriot, Yohann; Rodriguez-Vida, Alejo; Mamtani, Ronac; Yu, Evan Y; Nam, Kijoeng; Imai...
Journal:
Lancet oncology
Issue:
Volume 22:Issue 7(2021)
Page Start:
931
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search